Immune biomarkers in circulating cells of NSCLC patients can effectively evaluate the efficacy of chemotherapy combined with anti-PD-1 therapy

Cao et al. (Wed,) studied this question.

www.synapsesocial.com/papers/69d6c61841375cf86eed8a51 — DOI: https://doi.org/10.3389/fimmu.2025.1521708

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Elevated serum bilirubin levels are associated with improved survival in patients with curatively resected non-small-cell lung cancer· 2015 · 49 citations
2. Six-of-the-best: unique contributions of γδ T cells to immunology· 2013 · 1,180 citations
3. The blockade of immune checkpoints in cancer immunotherapy· 2012 · 13,663 citations
4. Development and Selection of the Human Vγ9Vδ2+ T-Cell Repertoire· 2018 · 84 citations
5. Co-stimulatory and co-inhibitory pathways in cancer immunotherapy· 2019 · 102 citations